Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.

MLA

Facchini, Gaetano, et al. “Second Line Therapy with Axitinib after Only Prior Sunitinib in Metastatic Renal Cell Cancer: Italian Multicenter Real World SAX Study Final Results.” Journal of Translational Medicine, vol. 17, no. 1, Aug. 2019, p. 296. EBSCOhost, https://doi.org/10.1186/s12967-019-2047-4.

APA

Facchini, G., Rossetti, S., Berretta, M., Cavaliere, C., Scagliarini, S., Vitale, M. G., Ciccarese, C., Di Lorenzo, G., Palesandro, E., Conteduca, V., Basso, U., Naglieri, E., Farnesi, A., Aieta, M., Borsellino, N., La Torre, L., Iovane, G., Bonomi, L., Gasparro, D., … D’Aniello, C. (2019). Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. Journal of Translational Medicine, 17(1), 296. https://doi.org/10.1186/s12967-019-2047-4

Chicago

Facchini, Gaetano, Sabrina Rossetti, Massimiliano Berretta, Carla Cavaliere, Sarah Scagliarini, Maria Giuseppa Vitale, Chiara Ciccarese, et al. 2019. “Second Line Therapy with Axitinib after Only Prior Sunitinib in Metastatic Renal Cell Cancer: Italian Multicenter Real World SAX Study Final Results.” Journal of Translational Medicine 17 (1): 296. doi:10.1186/s12967-019-2047-4.